Vera Therapeutics, Inc. — Director's Dealing 2022

Aug 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2022-08-12

Reporting Person: Fordyce Marshall (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-12	Class A Common Stock	M	20528	$2.8968	Acquired	157928	Direct
2022-08-12	Class A Common Stock	S	20528	$20.1578	Disposed	137400	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-12	Stock Option (right to buy)	$2.8968	M	20528	Disposed	2030-12-15	Class A Common Stock (20528)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022.

F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.59, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter.